Abstract
Objectives Among common head and neck cancers (HNCs), oropharyngeal cancer (OPC) patients have been identified as having a better dentition than many other tumour subsites. OPC consists of human papillomavirus (HPV)-positive and negative groups with different prognosis. The purpose of this study is to explore the presenting dental status of OPC patients based on HPV status at the pre-radiotherapy phase.
Materials and methods The study reviewed the dental panoramic radiographs of OPC patients seen at a dedicated pre-radiotherapy dental assessment clinic from 2011-2017. Only patients planned for intensity-modulated radiotherapy treatment were included within this study. Relevant dental and oncological data were collected.
Results A total of 316 patients with known HPV status (215 positive; 101 negative) were included for analysis. HPV-positive patients had significantly more teeth on attendance than HPV-negative patients (22.3 vs 19.0, p = 0.0000) and horizontal bone loss was less severe compared to HPV-negative patients (p = 0.0000). HPV-positive males and patients in the 55-64 decade presented with the best and most complex dentition.
Conclusion The rise of OPC with the prospect of long survival, particularly in HPV-positive patients, requires a dentition with adequate function and subsequent maintenance. The current study demonstrated that these patients have a complex dentition presenting new challenges to the dentist. This may explain in part the elevated osteoradionecrosis rate seen in this tumour group.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
NICE. Guidance on Cancer Services: Improving Outcomes in Head and Neck Cancers - The Manual. 2004. Available at https://www.nice.org.uk/guidance/csg6/resources/improving-outcomes-in-head-and-neck-cancers-update.pdf-773377597 (accessed July 2020).
The Royal College of Surgeons of England and The British Society for Disability and Oral Health. The Oral Management of Oncology Patients Requiring Radiotherapy, Chemotherapy and/or Bone Marrow Transplantation: Clinical guidelines. 2012. Available online at https://www.rcseng.ac.uk/dental-faculties/fds/publications-guidelines/clinical-guidelines/ (accessed September 2017).
Restorative Dentistry UK. Predicting and Managing Oral and Dental Complications of Surgical and Non-Surgical Treatment for Head and Neck Cancer: A Clinical Guideline.2016. Available at https://www.restdent.org.uk/uploads/RD-UK%20H%20and%20N%20guideline.pdf (accessed September 2017).
Beech N M, Porceddu S, Batstone M D. Radiotherapy-associated dental extractions and osteoradionecrosis. Head Neck 2017; 39: 128-132.
Wahl M J. Osteoradionecrosis prevention myths. Int J Radiat Oncol Biol Phys 2006; 64: 661-669.
Moon D H, Moon S H, Wang K et al. Incidence of, and risk factors for, mandibular osteoradionecrosis in patients with oral cavity and oropharynx cancers. Oral Oncol 2017; 72: 98-103.
Chang D T, Sandow P R, Morris C G et al. Do pre-irradiation dental extractions reduce the risk of osteoradionecrosis of the mandible? Head Neck 2007; 29: 528-536.
Patel V, Patel D, Browning T et al. Presenting dental status of head and neck cancer patients in the intensity modulated radiation treatment era. Br Dent J 2020; 228: 435-440.
Patel V, Patel D, Browning T et al. Pre-radiotherapy presenting dental status of the three most common head and neck cancer subsites in a novel radiation era. FDJ 2020; 11: 52-57.
Ernster J A, Sciotto C G, O'Brien M M et al. Rising incidence of oropharyngeal cancer and the role of oncogenic human papilloma virus. Laryngoscope 2007; 117: 2115-2128.
Sturgis E M, Cinciripini P M. Trends in head and neck cancer incidence in relation to smoking prevalence: an emerging epidemic of human papillomavirus-associated cancers? Cancer 2007; 110: 1429-1435.
Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71-96.
Grønhøj C, Jensen D, Dehlendorff C et al. Impact of Time to Treatment Initiation in Patients with Human Papillomavirus-positive and -negative Oropharyngeal Squamous Cell Carcinoma. Clin Oncol (R Coll Radiol) 2018; 30: 375-381.
de Martel C, Ferlay J, Franceschi S et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol 2012; 13: 607-615.
Mehanna H, Evans M, Beasley M et al. Oropharyngeal cancer: United Kingdom National Multidisciplinary Guidelines. J Laryngol Otol 2016; DOI: 10.1017/S0022215116000505.
Sturgis E M, Ang K K. The epidemic of HPV-associated oropharyngeal cancer is here: Is it time to change our treatment paradigms? J Natl Compr Cancer Netw 2011; 9: 665-673.
Boscolo-Rizzo P, Del Mistro A, Bussu F et al. New insights into human papillomavirus-associated head and neck squamous cell carcinoma. Acta Otorhinolaryngol Ital 2013; 33: 77-87.
Zaravinos A. An updated overview of HPV-associated head and neck carcinomas. Oncotarget 2014; 5: 3956-3969.
Kreimer A R Clifford G M, Boyle P, Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: A systematic review. Cancer Epidemiol Biomark 2005; 14: 467-475.
Louie K S, Mehanna H, Sasieni P. Trends in head and neck cancers in England from 1995 to 2011 and projections up to 2025. Oral Oncol 2015; 51: 341-348.
Chaturvedi A K, Engels E A, Pfeiffer R M et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 2011; 29: 4294-4301.
Chaturvedi A K, Engels E A, Anderson W F, Gillison M L. Incidence trends for human papillomavirus-related andunrelated oral squamous cell carcinomas in the United States. J Clin Oncol 2008; 26: 612-619.
Ang K K, Harris J, Wheeler R et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010; 363: 24-35.
Ragin C C, Taioli E. Survival of squamous cell carcinoma of the head and neck in relation to human papillomavirus infection: review and meta-analysis. Int J Cancer 2007; 121: 1813-1820.
O'Sullivan B, Huang S H, Perez-Ordonez B et al. Outcomes of HPV-related oropharyngeal cancer patients treated by radiotherapy alone using altered fractionation. Radiother Oncol 2012; 103: 49-56.
Li W, Thompson CH, O'Brien C J et al. Human papillomavirus positivity predicts favourable outcome for squamous carcinoma of the tonsil. Int J Cancer 2003; 106: 553-558.
Ang K K, Sturgis E M. Human papillomavirus as a marker of the natural history and response to therapy of head and neck squamous cell carcinoma. Semin Radiat Oncol 2012; 22: 128-142.
Beech N, Porceddu S, Batstone M D. Preradiotherapy dental extractions and health-related quality of life. Oral Surg Oral Med Oral Pathol Oral Radiol 2016; 122: 672-679.
Clough S, Burke M, Daly B et al. The impact of pre-radiotherapy dental extractions on head and neck cancer patients: a qualitative study. Br Dent J 2018; 225: 28-32.
Maier H, Zoller J, Herrmann A, Kreiss M, Heller W D. Dental status and oral hygiene in patients with head and neck cancer. Otolaryngol Head Neck Surg 1993; 108: 655-661.
Chaturvedi A K, Anderson W F, Lortet-Tieulent J et al. Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers. J Clin Oncol 2013; 31: 4550-4559.
NHS Digital. Adult Dental Health Survey 2009 - Summary report and thematic series. 2011. Available online at https://digital.nhs.uk/data-and-information/publications/statistical/adult-dental-health-survey/adult-dental-health-survey-2009-summary-report-and-thematic-series (accessed July 2020).
Tezal M, Sullivan M A, Hyland A et al. Chronic periodontitis and the incidence of head and neck squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 2009; 18: 2406-2412.
Centers for Disease Control and Prevention (CDC). Vital signs: current cigarette smoking among adults aged ≥18 years - United States, 2009. MMWR Morb Mortal Wkly Rep 2010; 59: 1135-1140.
Franceschi S, Bidoli E, Herrero R et al. Comparison of cancers of the oral cavity and pharynx worldwide: Etiological clues. Oral Oncol 2000; 36: 106-115.
Blot W J, Devesa S S, McLaughlin J K, Fraumeni Jr J F. Oral and pharyngeal cancers. Cancer Surv 1994; 19-20: 23-42.
Hong A M, Grulich A E, Jones D et al. Squamous cell carcinoma of the oropharynx in Australian males induced by human papillomavirus vaccine targets. Vaccine 2010; 28: 3269-3272.
Auluck A, Hislop G, Bajdik C et al. Trends in oropharyngeal and oral cavity cancer incidence of human papillomavirus (HPV)-related and HPVunrelated sites in a multicultural population: The British Columbia experience. Cancer 2010; 116: 2635-2644.
Blomberg M, Nielsen A, Munk C et al. Trends in head and neck cancer incidence in Denmark, 1978-2007: Focus on human papillomavirus associated sites. Int J Cancer 2011; 129: 733-741.
Braakhuis B J, Visser O, Leemans C R. Oral and oropharyngeal cancer in the Netherlands between 1989 and 2006: Increasing incidence, but not in young adults. Oral Oncol 2009; DOI: 10.1016/j.oraloncology.2009.03.010.
Mork J, Møller B, Dahl T et al. Time trends in pharyngeal cancer incidence in Norway 1981-2005: A subsite analysis based on a reabstraction and recoding of registered cases. Cancer Causes Control 2010; 21: 1397-1405.
Hammarstedt L, Lindquist D, Dahlstrand H et al. Human papillomavirus as a risk factor for the increase in incidence of tonsillar cancer. Int J Cancer 2006; 119: 2620-2623.
Reddy V M, Cundall-Curry D, Bridger M W. Trends in the incidence rates of tonsil and base of tongue cancer in England, 1985-2006. Ann R Coll Surg Engl 2010; 92: 655-659.
Hong A M, Martin A, Chatfield M et al. Human papillomavirus, smoking status and outcomes in tonsillar squamous cell carcinoma. Int J Cancer 2013; 132: 2748-2754.
D'Souza G, Kreimer A R, Viscidi R et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 2007; 356: 1944-1956.
Gillison M L, D'Souza G, Westra W et al. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst 2008; 100: 407-420.
De-ESCALaTE HPV: Determination of Epidermal growth factor receptor-inhibitor (cetuximab) versus Standard Chemotherapy (cisplatin) early And Late Toxicity Events in Human Papillomavirus-positive oropharyngeal squamous cell carcinoma. 2012. Available at http://www.isrctn.com/ISRCTN33522080 (accessed July 2020).
Post-operative Adjuvant Treatment for HPV-positive Tumours (PATHOS) (PATHOS). 2014. Available at https://clinicaltrials.gov/ct2/show/NCT02215265 (accessed July 2020).
Acknowledgements
Ethics: 19/EE/0224 - dental status, radiotherapy doses and subsequent implications in head and neck cancer patients - a retrospective cohort study.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
There are no conflicts of interest to declare by any of the authors for this submitted work.
Electronic supplementary material
Rights and permissions
About this article
Cite this article
Patel, V., Patel, D., Browning, T. et al. Pre-radiotherapy dental status of oropharyngeal cancer patients based on HPV status in a novel radiation era. Br Dent J (2020). https://doi.org/10.1038/s41415-020-1922-y
Published:
Version of record:
DOI: https://doi.org/10.1038/s41415-020-1922-y
This article is cited by
-
A cross-sectional study of the association of dental health factors with progression and all-cause mortality in men diagnosed with HPV-associated oropharyngeal cancer
BMC Oral Health (2024)
-
An audit of dental assessments including orthopantomography and timing of dental extractions before radiotherapy for head and neck cancer
British Dental Journal (2022)
-
The clinical effect of radiotherapy on pulpal microvasculature: a systematic review
British Dental Journal (2022)
-
The presenting dental status of solid tumours with bone metastases requiring bone-targeting agents - part 1: an overview
British Dental Journal (2022)
-
Famous for 15 minutes
British Dental Journal (2020)
